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Dr Randall B. Griepp (New York, NY). I have a few general
comments. One thing that I would suggest to the community of aor-
tic surgeons is that we considering using 1-year survival as the stan-
dard in reporting our results. In these extensive procedures that in
many cases take a substantial toll on the patient, I think the patient
who dies before 1 year has passed made a bad decision to have the
operation, or perhaps the surgeon made a bad decision. I would
suggest that 1-year survival is what we should look at rather than
30-day mortality.
The second suggestion is to present long-term mortality data
either in comparison with an age-matched control or as standard-
ized mortality ratios. For instance, in type A aortic dissections,
we know that the standardized mortality rate is between 2 and
2½ times normal, or 2 to 2½. Even after successful type A repair,
a patient is about 2 to 2½ times more likely to die each year than
is a member of the normal population. This makes it easy to com-
pare things from one series to the next. Since patients are of varying
ages and sex distributions, it also makes it easier to go from one
study to the next.
I have a couple of questions to start out with. Dr Kouchoukos
and Dr Fehrenbacher—and maybe Dr Kulik would like to
comment—what do you do about fluid retention after hypothermic
circulatory arrest (HCA)? In my experience, most of these patientsd at Aortic Surgery Symposium 2010, New York, NY, Friday, April 30, 2010.
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The Journal of Thoracic and Cardcome back from the operating room pretty heavy. How much fluid
do they accumulate on the average? How much does it affect extu-
bation time? When do you start diuresis?
Dr Nicholas T. Kouchoukos (St Louis, Mo). Fluid retention, I
believe, is probably real. We do not systematically weigh the
patients in the early postoperative period. They have a lot of mon-
itoring devices and tubes that make it very difficult to do. In gen-
eral, I think they do not come back overloaded, at least in terms
of their intravascular volume. We generally initiate gentle to mod-
erate diuresis in the operating room and continue it in the early post-
operative period. I think your point about fluid retention having
some influence on pulmonary function is probably also real.
Dr Griepp. What is your regimen for managing the coagulation
system at the end of an operation done with HCA? Do you use
thromboelastography? What do you give routinely, and what do
you give when things are bad?
Dr Kouchoukos. We do not give blood component therapy
routinely. In fact, a percentage of these patients, perhaps 10%,
and particularly those with aneurysms involving only the thoracic
aorta, received no blood products. We have used this technique
in a few Jehovah’s Witnesses and have been successful. We use
the thromboelastogram currently to guide our blood component ad-
ministration. Most of our patients, at least those with Crawford type
II or III aneurysms—the extensive ones—will receive one round of
fresh frozen plasma, as well as platelets and cryoprecipitate on oc-
casion. But we have no other specific regimen. We have not used
aprotinin since our early experience because it was so disastrous.
Dr John Fehrenbacher (Indianapolis, Ind). We have similar
results. With regard to fluid retention, other surgeons who have
used HCA have asked that question because of their concern that
the patients were so swollen. Our patients are cold and we are
running low flow: 1 L to 1500 L. We do not worry about running
calculated flows on the heart–lung machine when we are doing
the distal work. As long as I have a radial artery pressure of 40
mm Hg, I am happy, even as the patient starts to warm. We use
the typical diuresis that would be used with any pump: it is not
excessive. The patients are swollen, but, as I mentioned, the pro-
longed extubation rate was only 11%. Frankly, a lot of the reasons
for prolonged extubation are neurologic rather than lung problems.
From a coagulation standpoint, we give 10 g of alpha-
aminocaproic acid before turning the pump on; we give another 5iovascular Surgery c Volume 140, Number 6S S185
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and we are not routinely give clotting factors. Our mean blood
utilization—not intraoperatively, but for total hospital stay—was
4.7 units of blood. In general, we are frequently giving a platelet
pheresis pack, cryoprecipitate, or a fibrinogen concentrate, but
not always. My guess is that we are using those about half the time.
Dr Joseph S. Coselli (Houston, Tex). We do pretty much the
same thing. We do the minority of cases under HCA. If we put
them on pump, we are putting them on pump to cool them down,
and generally it is a selected group of patients: it is not across the
board.
Although he blew past it, Dr Fehrenbacher pointed out some-
thing that I think is critical from a neurologic standpoint in these
patients. When I am working on the proximal anastomosis in and
around the arch, I have a clamp on the descending thoracic aorta,
and the pump flow is about 2 L/min. I think that the filling of blood
in the arch that is emanating back toward you that you have to suck
away is extremely important in keeping out air, and you float out
some debris. I think I saw that in his film. I think it is important.
The only thing that I would add with the bleeding issue is to keep
in mind the use of factor VII from time to time if you get into a really
serious coagulopathy.
Dr Griepp. Thank you. I will add my two cents. I think the
biggest problem with postoperative fluid retention is if diuresis is
conducted too quickly while the capillaries are still leaking and
the patient becomes hypovolemic, even though he is 10 kg
overweight. I believe the coagulation defect of hypothermia is
platelet function; I think having a couple packs of platelets ready
is a good idea. I actually think fresh frozen plasma is probably
harmful, but I will leave it at that.
Dr Fehrenbacher.What we have noticed (and it is very interest-
ing; we have a series now), is that when the patient is hypothermic,
the platelet count drops dramatically. As the patient warms, the
count comes right back up. For a long time we were ordering plate-
lets and even transfusing on pump. But once I started using
BioGlue adhesive (CryoLife, Inc, Atlanta, Ga) to seal the needle
holes, I got a little more bold about not ordering platelets, and plate-
let counts that were 30,000 at 15C were 85,000 at 37C. So we are
a little less aggressive with platelets.
Dr Griepp. One of the issues with extensive stenting is the left
subclavian artery. Perhaps Mr Chesire and Dr Kurutani would like
to comment. How many of your patients had coverage of the left
subclavian artery? These were all more distal aneurysms, is that
not correct?
Mr Nicholas J. W. Chesire (London, United Kingdom). I was
reasonably gentle in the way I framed our experience. Early on in
this series, we had a malignant combination, I think, of ignorance
about the need to keep the left subclavian in circuit and a kind of
overblown confidence in this new operation. We did all of our first
45 cases just blindly covering the left subclavian if we needed to.S186 The Journal of Thoracic and Cardiovascular SurWe never revascularized it. All our thoughts and concentration
were on arm ischemia. I remember talking at several meetings
and saying that, in our thoracic endovascular aneurysm repair
(TEVAR) and thoracoabdominal program, we had to go back
and revascularize only 2 patients, both young men with old transec-
tions who were fit and active and had arm claudication. Actually, I
think a combination of taking on the wrong patients and not revas-
cularizing the left subclavian gave rise to the uptick in spinal cord
injury that we had. We really had to readdress our whole program.
As I said, the only patients in whom we do not revascularize the left
subclavian now are those with acute dissection in whom there is
a great deal of backwash. We are only doing the thoracic portion,
where the figures suggest that there is a relatively low incidence
of spinal cord injury. Everyone else gets a left subclavian in circuit
now.
Dr Toru Kuratani (Osaka, Japan). Usually we use much lon-
ger stent grafts for thoracoabdominal aortic aneurysms. The collat-
eral circulation is very important, and the left subclavian artery is
very important for the collateral circulation. Any time we obstruct
the left subclavian artery, we need to assure the patency of left sub-
clavian artery flow. The hypogastric artery is also very important to
prevent paraplegia or paraparesis. We check flow in the hypogastric
artery and left subclavian artery preoperatively.
Dr Griepp. I have 1 final question for the hybrid surgeons. Do
you ever do these procedures in 2 stages? I know there are access
problems in many cases, but is there a situation in which you do
your debranching and then say that is enough for today; let’s
come back in a week or so?
Mr Chesire. We have a kind of division of views in our unit. I
am quite keen to split the procedure in two. It has often been
a very long day and the patient is coagulopathic. Paradoxically,
if it has been long and the patient is cold, I suppose it is actually
slightly better for the spinal cord. We have had interval ruptures in
2 cases, and in our European paper we described 3 interval
ruptures in that short period of time. It happens if the patients
are sick after a large abdominal operation and there is a delay in
getting the stent graft in.
Dr Griepp. What percentage of yours in this series are 2-stage
procedures?
Mr Chesire. I cannot remember exactly in that series. It is 18 of
110 in the European series, or 18.9%.
Dr Kuratani. Usually we use a 2-stage operation, because with
a debranching operation added to an accessory operation, some-
times there is too much blood loss. At such a time, blood pressure
is unstable, and the stent graft operation has a risk of paraplegia. We
do the bypass operation on the first day, and the next day we try the
stent graft surgery. In the presentation, perhaps 95% of the patients
had a 2-stage operation.
Dr M. Schepens (Brugge, Belgium). I have 2 short questions, 1
for Dr Coselli and 1 for Dr Kouchoukos or Dr Fehrenbacher, who
use deep hypothermia. The first question concerns the technique of
giving intravenous dye after reperfusion of the kidneys. Joe, are
you comfortable with that? Do you think it is useful to give intra-
venous dye and to check the time that it appears in the urine as
a marker of postoperative renal function?
The second question is in regard to the use of cerebrospinal fluid
(CSF) drainage and full heparinization. Have you seen any compli-
cations related to that?gery c December 2010
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rare circumstances, we use it for urine clearance routinely and really
have not seen a downside to that.
Dr Schepens. Exactly. We use it all the time. We found that
when the dye appeared in the urine within 30 minutes after reperfu-
sion, there was a very low chance that renal failure would develop
afterward.
Dr Coselli. I find it most useful when I have an atrophic or ab-
sent left kidney, I have reattached the right kidney, and I am con-
cerned about the circulation, as it is otherwise hard to manage.
Dr Griepp. Joe, what dye are you talking about? Is it methylene
blue?
Dr Coselli. He is not talking about intravenous contrast for arte-
riography. He is talking about dye for urine clearance.
Dr Schepens. Indigo carmine blue.
Dr Kouchoukos. We have not used any contrast, and since we
have gone to using the branch grafts for the renal and visceral
arteries, we measure flow in these arteries before we leave the op-
erating room. We have had a similar experience to Dr Coselli with
one kidney, but generally we are certain that there is adequate flow
in the renal arteries at the conclusion of the procedure.
With regard to CSF drainage and full heparinization, this is a real
concern. We procrastinated a bit before implementing the use of
CSF for that reason. Since we have been using it, however, our com-
plication rate has not been different from what you heard presented.
A subdural hematoma, which required surgical drainage, developed
in 1 of the 53 patients in whom CSF drainage was used, but she sur-
vived. Obviously one has to be careful about use of CSF drainage
with full heparinization. If we get a bloody tap or encounter any
other difficulty with insertion of the catheter, we abandon its use.
Dr Fehrenbacher. I do not use dye, but what I expect to see
once we are off-pump and have pulsatile flow is at least 100 to
200 mL of urine every half hour. If I see 20 or 30 mL, then I
know I probably have a technical problem with the bypass.
With regard to CSF drainage, our beliefs are the same as those that
have been outlined. We use motor evoked potentials. If the patient is
warm and has pulsatile flow, and the motor evoked potentials do not
come back immediately to baseline, then we put a drain in before we
leave the operating room. Otherwise, we do not drain CSF routinely,
except when there is evidence of delayed spinal cord injury.
Dr J. Bavaria (Philadelphia, Pa). Martin, this is an excellent se-
ries with a mean follow-up of almost 5 years—very good long-term
data. Have the endoleak rates improved over time as the grafts have
improved? The short grafts were disastrous for endoleaks. I would
like to know whether your 1-month or 30-day endoleak rate has
changed over the past 10 or 12 years that you have been doing this.
DrMartin Czerny (Berne, Switzerland). The endoleak rate has
definitely decreased over time. From the very beginning, we
followed a very extensive policy of long landing zones. However,
when we reflect on the past 12 years of implementing this therapy, I
think the conclusion is that the longer the landing zone and the
lower the number of prostheses, the higher the probability of suc-
cess both early and long term. It is clearly the case that the rate
of type III endoleakage has been dramatically reduced over time.
Dr Bavaria. I have a second follow-up question that is similar. I
am interested in your type II subclavian endoleaks, which we never
have because we always take care of the subclavian artery and
never over-stent it without either ligating it or coiling it orThe Journal of Thoracic and Cardsomething. What is your policy now toward the subclavian artery
with regard to the proximal landing zone?
Dr Czerny. In the elective setting, we use transposition in every
case. The cases I showed were all emergency settings in which we
did not have any time to revascularize in advance, and we got a feel
for that in the midterm.
Dr M. P. Siegenthaler (Bethesda, Md). I have a question for
Martin Czerny. What was the incidence of late endoleaks in stent
grafts with a perfect result initially? I assume a lot of the problems
you observed were difficult cases in which you had problems from
the beginning. However, how many have you seen that were perfect
initially, with no type I or type III endoleak, that on late follow-up
had endoleaks?
Dr Czerny. That is a very good question. The answer is none of
them, just two type V endoleaks. These were the ones, of course,
that were not predictable. As we know, the first-generation stent
grafts had a plasma leakage problem. The grafts that were ideal
at the beginning remained stable over the years.
Dr Siegenthaler. You made the point that long-term follow-up
is important, so couldn’t you make the point that if it is perfect
early, it is very likely that it will stay that way?
Dr Czerny. That is a very good question. There are 2 points.
Aortic disease will develop in 10% of our patients in other seg-
ments over the years. I think the surveillance of other segments is
probably more important than the surveillance of a primary perfect
result. Furthermore, we have detected 15 or 16 newly diagnosed
asymptomatic malignancies in these patients, primarily bronchial
carcinoma but also colon carcinoma, which we were able to detect
at a very early stage because we monitored them for aortic disease.
Therefore, I think that routine follow-up computed tomographic
(CT) scans have their merits for all these reasons.
MrChesire. It is a good question, though. It reflects some of the
thinking and some evidence in the abdominal aorta. If there is
a good infrarenal neck and long engagement of the iliacs, then
the incidence of stent graft problems with the modern systems is
very low. However, where I would take issue with you is in assum-
ing in any of these cases that the graft sits perfectly. When you have
to go around that evil-shaped arch and there are large numbers of
stent grafts overlapping each other over a very long segment,
then you can never feel perfectly comfortable that this is okay. I
agree with Martin. These patients need follow-up all the time.
Dr Coselli. This is a group of patients receiving long-term fol-
low-up. They do pretty well. What we have suggested to many of
them is that if we are going to follow up the rest of the aorta with
a CT scan and we do not have an early endoleak that we are observ-
ing, we not give them intravenous contrast in those follow-up stud-
ies and reduce that additional impact.
DrH.Ogino (Suita City, Japan).My concern is about the recon-
struction of the visceral arteries, including the intercostal artery.
My question is to Dr Kouchoukos and Dr Coselli. How often did
you encounter aneurysms after the island technique? And Dr Co-
selli, how often do you use your Vascutek branched graft (Terumo
Corporation, Tokyo, Japan)? I like a branched graft. Could you
please answer?
Dr Kouchoukos. We have seen intercostal patch aneurysms -de-
velop late postoperatively. One of the reasons, I think, is that, partic-
ularly for patients with chronic dissections, we have been very liberal
about implantating large numbers of intercostals because most ofiovascular Surgery c Volume 140, Number 6S S187
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with endovascular grafting techniques, and we have had very good
success in treating them in this manner, assuming that there is a suit-
able landing zone on either side. We have used branched grafts in the
hope of eliminating patch aneurysms of the visceral patch, and we
have not had any problems with this approach.
DrGriepp. I could point out that if you do not use the intercostal
arteries in the first place, you will not have that problem.
Dr Kouchoukos. I still have a little anxiety about ligating all of
the intercostal arteries, particularly when operating on a 30- or 35-
year-old patient with Marfan syndrome. I just do not have the cour-
age to do that.
Dr Coselli. I do not know what the exact incidence is of patch
aneurysms. From following Dr Crawford’s patients and our own,
I guess we probably have operated on 40 or so visceral patches.
It is related to time and also to the disease process, as well as to hy-
pertension. Connective tissue disorder, dissection, and hyperten-
sion are the things that we worry about. With intercostal patch
aneurysms in recent years, we have had the exact same experience:
we put stent grafts across these, and at least to date, we really have
not had any neurologic sequelae from that. How often do I use the
branch graft? Unlike Dr Kouchoukos, I use it selectively in the pa-
tients that I described. Also, any time we redo a patch aneurysm, if
we are going to do it open, we will virtually always use a branch
graft. In our overall experience, it is a little less than 10%
Dr Kouchoukos. Dr Kulik may want to comment on this be-
cause he did all of the groundwork for our publication on this sub-
ject. If you look at the literature, there is very little written about the
prevalence of patch aneurysms. There are scattered series and scat-
tered case reports, particularly regarding visceral patch aneurysms.
One of the problems, of course, is that these probably go undetected
in a substantial number of patients unless they are scanned on a rou-
tine basis. Therefore, the actual prevalence may be higher than has
been reported.
Mr Chesire. One thing that has not been raised is the use of
branch or fenestration technology for patch aneurysms, particularly
on the visceral segment, because they are straight and they get good
Dacron landing zones top and bottom. We have not done any yet,
but we are looking out for them.
Dr Alexander Kulik. I would like to follow up on Dr Kouchou-
kos’s point about the incidence of patch aneurysms. Having re-
viewed the literature to evaluate the incidence of visceral patch
aneurysms, I found that it is anywhere between 4% and 8%. There
was a series from Italy that estimated the incidence at 4% and a se-
ries from Johns Hopkins that reported a visceral patch aneurysm in-
cidence of 7.5%. With regard to intercostal patch aneurysms, in
a review of Dr Kouchoukos’s experience, we noted that 7.1% of
patients treated with intercostal artery reimplantation at the time
of the initial aortic surgery had intercostal patch aneurysms develop
over long-term follow-up. A number of these patients were treated
very successfully with stent graft techniques.
DrGriepp.We have used Dr Spielvogel’s graft for branch graft-
ing, and it is very useful if you want to plan for possible later stent-
graft implantation. It gives you a lot of freedom, either bringing it
from below or bringing it from above, and leaving a large part of the
main graft available for a landing zone.
Dr J. Bachet (AbuDhabi, United Arab Emerates). I have a small
technical question for Dr Kouchoukos and Dr Fehrenbacher. In theS188 The Journal of Thoracic and Cardiovascular Surfew patients in whom I have used deep hypothermia during replace-
ment of the thoracoabdominal aorta, I have noted that it was
difficult, at least for me, to deair the arch. I remember 1 patient
who most probably had an air embolus when we resumed proximal
bypass. What are your techniques to safely deair the arch in deep
hypothermia before resuming cardiopulmonary bypass?
Dr Kouchoukos. I can remember when we first started doing
this, and I also remember seeing Dr Crawford do a case. I was abso-
lutely terrified about the probability of entrapping air. Dr Fehren-
bacher has a little different technique from ours, but what we do is
initiate the venous perfusion retrogradely through the venous can-
nula as we are completing the proximal aortic anastomosis. If this
is done for several minutes, the whole arch will fill with blood. As
I mentioned in my presentation, if you have a vent in the left heart,
you have to be sure that vent is not operating while you are filling the
proximal aorta, so that you do not suck air into the heart. These
maneuvers, in our experience, are satisfactory. Dr Fehrenbacher con-
tinues perfusion from below, which accomplishes the same thing.
Dr Bachet. Are you saying that you have a systematic shunt
between your arterial line and your superior vena cava line in
your bypass system?
Dr Kouchoukos. That is correct, and if you have the head in
a dependent position, you can generally fill the arch and the graft
without difficulty.
Dr P. Aranda (Malaga, Spain). Dr Coselli, do you think there is
a minimum number of cases a hospital should be doing to do a thor-
acoabdominal operation or should these patients be referred? What
do you think is the minimum number of patients per year to start
one of these programs? The second question is to Dr Chesire
regarding hybrid revascularization of the visceral arteries. I would
like to know your opinion about using the ascending aorta as the
inflow for your viscerals as proclaimed by Dr Exposito in Italy,
among others.
Dr Coselli. I am not absolutely certain how to answer. I think it
is more than just a surgeon’s skill level. You have to build a team
around some of these complex aortic cases to do a wide variety of
things that we have talked about over the last couple of days: the
techicians, the anesthesiologists, the perfusion team, and the post-
operative care management personnel. It takes a really focused
effort to have really good results. There are actually some data
with regard to the mortality rates of thoracoabdominal aneurysms
from some articles that have been written on Medicare data. In
my recollection, if you are not doing at least 25 a year, your mor-
tality rate begins to rise in a statistically significant fashion. I am
not absolutely certain of that 25% figure, but I think that is fairly
close. I personally think the number actually may be a little bit
higher than that.
MrChesire. I agree very much with Joe’s point. There is a good
evidence base in infrarenal aneurysm repair, which is infinitely
easier, with a cutoff point beginning with a minimum of 35 cases.
So one would have thought the thoracoabdominal repair, needing
a team and everything else, is going to require even an even greater
number of cases to be sure of getting good results.
Dr Aranda. Can you comment on the ascending aorta as an in-
flow for the visceral vessels?
Mr Chesire. We have done 2 of those, and it is very successful.
It is a nicer looking procedure than this rather ugly retrograde graft.
It is just very invasive, and you cannot help thinking should yougery c December 2010
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have done that much surgery.
Dr Griepp. Let me ask a question for the surgeons and hybrid
personnel here. What about preoperative workup? What do you re-
quire in your patients before you take them to the operating room to
do one of these big procedures? Should they be catheterized?
Should they have a stress test? What else? Do they need a pulmo-
nary function test or a walking test?
Dr Kouchoukos. For patients with thoracoabdominal or exten-
sive descending thoracic aneurysms, and for any patient over the
age of 40 to 45 years, we perform coronary angiography as the
principal screening study. We do not rely on stress testing or thal-
lium testing. Instead of wasting considerable time and money doing
noninvasive testing, it is much quicker and possibly cheaper to do
a cardiac catheterization. As Dr Fehrenbacher indicated in his
presentation, a not insignificant number of patients will require cor-
onary artery bypass grafting or stenting before aneurysm repair, and
this has been our experience as well. In addition, if more than mild
aortic regurgitation is present preoperatively, aortic valve replace-
ment will be necessary before proceeding with the aneurysm repair.
With regard to pulmonary function, as Dr Fehrenbacher indi-
cated, we have operated on patients who are oxygen-dependent.
We do not rely heavily on pulmonary function tests. Somebody
who has a massive aneurysm impinging on the left lung may do sur-
prisingly better than you expect once you remove the aneurysm and
the lung expands.
Dr Griepp. Should you be able to walk up a flight of stairs?
Dr Kouchoukos. No. As I indicated, some of these patients are
oxygen-dependent. They are not walking anywhere.
Dr Fehrenbacher. My beliefs are exactly the same. Especially
with cold circulatory arrest, we are fibrillating all these hearts. Early
on, I was doing stress tests, until I had the first patient go back to the
unit after a 6- or 7-hour operation and have fibrillation. I could not
resuscitate the patient, and at autopsy he had a very proximal left
anterior descending lesion, but had had normal stress test results.
That is unusual, but now they all get catheterized. I also think
that some of the reasons that we have a 53% 10-year survival in
this group of patients is probably because a lot of people die post-
operatively from coronary artery disease. We are fixing that as we
go: left-sided lesions, left anterior descending arteries, circumflex
arteries. When you are doing a descending Crawford I, or even
a Crawford II, it is painful, but we bypass the coronary arteries
with veins and hook the veins to the Dacron graft in the distal
arch or proximal descending aorta.
Dr Coselli. What we do is fairly similar. I even try to evaluate
the younger patients with a perfusion scan or a stress test. I figure
that if I am evaluating them for an aneurysm, they already have
a major risk factor, so I want to be careful. We are fairly aggressive
about catheterizing our older patients. Even putting in some coro-
nary stents and then doing a thoracoabdominal aneurysm procedure
a short time afterward is worrisome. I worry about those stents
somewhat; even that is not a fail-safe situation. We do not do an ar-
teriogram on patients undergoing thoracoabdominal aneurysm sur-
gery anymore. We rely almost exclusively on the CT scan, with the
exception of patients having a hybrid approach. I like to get an ar-
teriogram on those patients before we subject them to that particular
procedure. I am not a huge enthusiast of the hybrid approach, but
we have done a number of them.The Journal of Thoracic and CardMr Chesire. We still use dobutamine stress echocardiography
as a screening test and catheterization as needed. Our coronary
mortality is not our biggest problem. Amazingly, despite almost
starting this program to avoid multiple organ dysfunction and sys-
temic inflammatory response, we still see it in these patients, and
that is the commonest cause of death that we have, unless there is
some other catastrophe. We focus quite a bit on the kidneys as
well, and we still do nuclear split function scanning, because we
are very keen on making sure we revascularize, particularly if
they have more than one renal artery. That is a really big issue
for the hybrid approach. The final point echoes what Joe said: we
really get such good images on the CT now that we have just about
given up doing preoperative angiography on any of the patients.
Dr Kulik. I recently had a patient who had a coronary angio-
gram the day before descending thoracic aortic stent graft repair,
and there was a high-grade focal lesion in the circumflex coronary
artery. The question was, what do you do with it? If you are going to
treat it with a coronary stent, the cardiologist is going to request
treatment with clopidogrel (Plavix) for a few months. However,
the anesthesiologists would not be willing to place a CSF drain at
time of stent graft surgery with clopidogrel on board. Is the best
treatment coronary stenting and delaying aortic stent graft repair?
Or should we forgo the CSF drain? Or should we leave the circum-
flex artery lesion alone? This is a complicated decision that requires
many factors to be considered.
Dr Bavaria. I would like to revisit the type II indication situa-
tion, and maybe Marc can comment. We have today Dr Griepp’s
group with a 15% to 20% mortality rate for type II. If you look
at all the data from the presentations today, you are looking at
a 20% to 30% combined paraplegia, stroke, and death rate for
type II thoracoabdominal aortic aneurysms. Maybe Joe’s data are
a little better, but everybody else’s are not. What I am wondering
is whether we should be using 5.5 or 6 cm for these type II aneu-
rysms, or whether it should be 7 cm if you look at the Yale data re-
garding rupture risk versus complication rates and the natural
history of a 7-cm aneurysm in a patient with a body surface area
of 2. What is everybody using for type II thoracoabdominal aneu-
rysms as an indication for surgery?
Dr Czerny. I think we actually have quite reliable data on the
natural history, especially from the Yale group. For us, 6 cm is
the cutoff based on the balance of the remaining risk of the opera-
tion and the threat of the natural course of the disease.
Dr Griepp. Let me ask also your comment on whether there is
a difference between dissection and degenerative or atherosclerotic
aneurysms?
Dr Czerny. It is 6 cm for both.
Dr Coselli. We basically use 6 cm also, but we also try to look at
the rate of growth. We look at a family history of problems. It is as
though we are walking up a flight of stairs. I try to index the aneu-
rysm somewhat to the size of the patient. I think age must be in-
cluded as a factor. We are more aggressive in patients with
dissection and connective tissue orders of all kinds.
Dr Kouchoukos. I mentioned this yesterday, Randy, but I think
you do have some data indicating that the natural history of the pa-
tients with dissection in the descending thoracic or thoracoabdomi-
nal aorta is not as good as it is for the degenerative disease in terms
of the risk of rupture. We tend to be a little bit more aggressive with
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operation in that situation. For the degenerative aneurysm, I think
we would wait until 6 cm in most patients. One of the dilemmas
is the older patient, 72 or 73 years old, who has an aneurysm that
is growing slowly. Do you wait 3 or 4 or 5 more years until renal
insufficiency or more pulmonary insufficiency or cardiac problems
develop, or is it better to go ahead when everything is optimal? I do
not have a specific answer to that question, but I think it is a di-
lemma that we face not infrequently. Sometimes we are tempted
to ignore the diameter threshold and operate earlier.
MrChesire.We use 6 cm as a minimum point. I believe the data
indicate that the rupture risk for that given size is higher for women,
but the outcomes are poorer for women in our series, so they kind of
balance each other out and we carry on using the same thing. I
would agree with what was said already about dissection and con-
nective tissue disease.
Dr Fehrenbacher. As I mentioned, we are probably more
aggressive: our threshold is 5.5 cm in general. We take into consid-
eration age, comorbidities, and family history. Clearly, dissection
in our experience has a worse prognosis than atherosclerosis, so
we are more aggressive with dissection than with atherosclerosis.
However, in general, I see the hinge point and I see the numbers.
There was a great review 2 years ago in a supplement to The
Annals of Thoracic Surgery that reviewed all this as it has been re-
viewed here today, and that hinge point is around 6 cm. Where I
grew up in southern Indiana, you always try to get the punch in be-
fore somebody punches you. So if the punch comes at about 6 cm,
we go for 5.5 cm.
Dr Kuratani. Usually we use 66 mm in the nondissected aneu-
rysm. In the dissection, the rupture risk is likely very high, so weS190 The Journal of Thoracic and Cardiovascular Suruse 55 mm or so. In Marfan syndrome, our indication for surgery
is 50 mm or even lower.
Dr Kulik. Just to clarify, if memory serves me well, the hinge
point for descending thoracic aortic aneurysms is 7 cm. That is
the basis for justifying aortic surgery at 6 cm, before getting to
that hinge point. In the ascending aorta, the hinge point is 6 cm,
justifying treatment at 5 or 5.5 cm (Coady MA, Rizzo JA, Ham-
mond GL, Kopf GS, Elefteriades JA. Surgical intervention criteria
for thoracic aortic aneurysms: a study of growth rates and compli-
cations. Ann Thorac Surg. 1999;67:1922-6).
Dr Griepp. I think we also have to keep in mind that these data
are pretty old now and that the natural history of some of these
diseases may be changing with beta-blockade, more careful surveil-
lance, and treatment of blood pressure. That has to be kept in mind.
There is one dilemma. You see the thoracic aorta getting longer
and longer, and you see this big ugly aneurysm curling, and you
say: ‘‘Call the thoracic endovascular aneurysm repair (TEVAR)
guys; this looks like a mess.’’ And they say: ‘‘We can’t do that:
it’s too tortuous; the landing zones are twisted.’’ So you are going
to have to operate anyway. Sometimes you can wait too long, I sup-
pose. But I think the issue of size is important.
One other situation that I am sure you all know about concerns
the patient a few months after an acute type B dissection which was
treated very successfully medically, with an aorta by the time he left
the hospital of about 4 cm. When you see him a few months later, it
is 4.7 or 5 cm. In those high-risk patients, 5 cm is a very conserva-
tive number. If it is within a year or 2 of an acute type B dissection
and the diameter is more than 5 cm, I think these patients definitely
should be operated on. I think we have some data from the Far East
that will support that.gery c December 2010
